Class summary at a glance.

Every drug in the Cortisol Synthesis Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 1tracked in Part D
CY24 Part D spend: $59.0Mcombined across class
Total Rx claims: 2K533 unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Levoketoconazole

Brand: Recorlev · 2K Part D claims (CY24) · 533 beneficiaries · First FDA approval: 2021-12-30

Brand-only (no generics) 27 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $59.0M

Class share

100%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.